Daiwa Securities Group
ALGS icon

Daiwa Securities Group’s Aligos Therapeutics ALGS Stock Holding History

Daiwa Securities Group’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5
Closed – – 1313
2022
Q3 		$0 Hold
5
– – ﹤0.01% 1334
2022
Q2 		$0 Hold
5
– – ﹤0.01% 1349
2022
Q1 		$0 Hold
5
– – ﹤0.01% 1373
2021
Q4 		$1K Buy
+5
New +$1.82K ﹤0.01% 1323

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Daiwa Securities Group's ALGS Position: Q4 2022 in Review

Daiwa Securities Group sold out of Aligos Therapeutics (ALGS) in Q4 2022, closing a stake of 5 shares.

Daiwa Securities Group first reported a position in ALGS in Q4 2021 and held it in 4 quarters. The position peaked at $1K in Q4 2021. 38 funds tracked by Wall St. Rank hold ALGS as of Q4 2022.

  • Daiwa Securities Group reported no remaining Aligos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Daiwa Securities Group sold 5 Aligos Therapeutics shares in Q4 2022.
  • Daiwa Securities Group first reported a position in Aligos Therapeutics in Q4 2021 and held it in 4 quarters.
  • Daiwa Securities Group's Aligos Therapeutics position peaked at $1K in Q4 2021.
  • 38 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2022.

Based on Daiwa Securities Group's 13F filing for Q4 2022, filed 6 Feb 2023.